Nicholas Rogerson has worked in the pharmaceutical industry for nearly 25 years in major companies as well as in consulting and investment banking. He specialises in business development and advises pharma and biotech companies, investment banks and venture capitalists on issues such as partnering, M&A and strategic exits. Following an early scientific career, he started in regulatory affairs and then rapidly progressed to business development. Mr. Rogerson has been Global Head of Pharmaceutical Business Development at Hoffmann-La Roche, Head of Corporate M&A for Novartis and Managing Director for Bear Stearns, leading their European Pharma M&A efforts. Mr. Rogerson has an MBA from Cranfield University School of Management (UK) as well as BSc & MSc life-sciences degrees from Sheffield and London Universities respectively. He is also a graduate of The Wharton School's AMP (Advanced Management Program) in the USA.
Commenting on the appointment, Johanna Holldack, CEO of Telormedix, said: “I would first like to thank Jean-Phillippe Tripet for all of his outstanding contributions and efforts as Chairman of the Board- he has now taken on the position of Vice-Chairman of the Board and will continue to support Telormedix alongside fellow board members Alain Schreiber, M.D, Proquest Investments, Skip Holden, M.D., Cedars Sinai Medical Center, and myself. I am also delighted to welcome Nick to the Telormedix board and believe that his substantial experience on the pharma side of business development and of corporate transactions will be very valuable. I feel that he will help us significantly advance Telormedix and secure future success by advising and guiding on strategic decisions as we continue to expand our pipeline and further develop our business.”
Nicholas Rogerson added: “Under the leadership of Johanna Holldack, Telormedix has made significant progress in its clinical development of its TLR7 agonist programs, particularly the Company’s lead topical bladder cancer treatment. I’m excited to be affiliated with Telormedix and look forward to giving my input at such an important phase of development for the company.”
About Telormedix
Telormedix is a clinical stage biopharmaceutical company founded in 2008 and focused on targeted immunity in the treatment of cancer and inflammatory diseases. The Company’s lead product, TMX-101, is entering the clinic for the localised treatment of bladder cancer, a disease of unmet medical need. TMX-101 is a new formulation of a clinically active small molecule compound specifically optimized for treating bladder cancer. Telormedix also has an additional pipeline of product candidates targeting cancer and autoimmune diseases. The Company’s discovery capability, managed under an exclusive licensing agreement, draws on years of experience and the world class research standing of its academic partner. Located in Switzerland, Telormedix is led by a highly experienced management team and backed by an international consortium of venture capitalists including Aravis Venture (Basel, Switzerland), Proquest Investments (Princeton-San Diego, USA) and Generali Insurance Group (Italy).
Further information on Telormedix can be found at www.telormedix.com.
Further Information:
Johanna Holldack
CEO
Telormedix SA
t: +41 (0)91 610 7000
e: jholldack@telormedix.com
Robert Mayer
Senior Account Manager
College Hill Life Sciences
t : +49 (0)89 5238 8030
e: robert.mayer@collegehill.com
